Astellas Pharma chief strategy officer Adam Pearson stated: “We believe that technologies such as Sangamo’s STAC-BBB capsid could prove critical in helping us deliver effective ...

At the time, Astellas’ chief strategy officer Adam Pearson put the deal in the context of the company’s attempts to expand its gene therapy pipeline “to help a broader range of people living ...

We are delighted to license STAC-BBB to Astellas to advance potential treatments for neurological diseases with significant unmet medical needs." Adam Pearson, Chief Strategy Officer, Astellas ...